The broad program of research supported by NIH is essential for advancing our understanding of basic biological functions, reducing human suffering, and protecting the country against new and re-emerging disease threats. Biomedical research is also a primary source of new innovations in health care and other areas.
Exciting new NIH initiatives are poised to accelerate our progress in the search for cures. It would be tragic if we could not capitalize on the many opportunities before us. The development of a universal vaccine to protect adults and children against both seasonal and pandemic flu and development of gene chips and DNA sequencing technologies that can predict risk for high blood pressure, kidney disease, diabetes, and obesity are just a few of the research breakthroughs that will be delayed if we fail to sustain the investment in NIH.
As a result of our prior investment, we are the world leader in biomedical research. We should not abdicate our competitive edge. Without adequate funding, NIH will have to sacrifice valuable lines of research. The termination of ongoing studies and the diminished availability of grant support will result in the closure of laboratories and the loss of highly skilled jobs. At a time when we are trying to encourage more students to pursue science and engineering studies, talented young scientists are being driven from science by the disruption of their training and lack of career opportunities.
Rising costs of research, the increasing complexity of the scientific enterprise, and a loss of purchasing power at NIH due to flat budgets have made it increasingly competitive for individual investigators to obtain funding. Today, only one in six grant applications will be supported, the lowest rate in NIH history. Increasing the NIH budget to $32.0 billion would provide the agency with an additional $1.36 billion which could restore funding for R01 grants (multiyear awards to investigators for specified projects) back to the level achieved in 2003 and support an additional 1,700 researchers while still providing much needed financial support for other critical areas of the NIH portfolio.Unfortunately, the released White House budget (PDF) will only provide a minimal increase in annual NIH funding from $29.9 billion to $ 30.2 billion, which is still lower than the pre-sequester $30.6 billion.
It is much lower than what FASEB had suggested and it is going to be increasingly difficult for US biomedical research to sustain its competitive edge. The White House budget also emphasizes neuroscience and Alzheimer's research:
Biomedical research contributes to improving the health of the American people. The Budget includes $30.2 billion for NIH to support research at institutions across the United States, continuing the Administration’s commitment to investment in Alzheimer’s research and NIH’s contribution to the multiagency BRAIN (Brain Research through Advancing Innovative Neurotechnologies) initiative. The Budget increases funding for innovative, high-risk high-reward research to help spur development of new therapeutics to treat diseases and disorders that affect millions of Americans, such as cancer and Alzheimer’s disease. The Budget includes funding for a new advanced research program modeled after the cutting-edge Defense Advanced Research Projects Agency (DARPA) program at the Department of Defense. NIH will also implement new policies to improve transparency and reduce administrative costs. The Opportunity, Growth, and Security Initiative includes an additional $970 million for NIH, which would support about 650 additional new grants and further increase funding for the BRAIN and DARPA-inspired initiatives, and invest in other critical priorities.
While this is good news for neuroscientists, the essentially flat NIH budget will force the NIH to cut funding to basic biomedical research in non-neuroscience areas including basic cell biology, molecular biology and biochemistry.
The outlook for US biomedical research remains gloomy.